Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and sustained clinical efficacy for up to 1 yea...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Adis, Springer Healthcare 2024-08-01
Sarja:	Rheumatology and Therapy
Aiheet:	Psoriatic arthritis Efficacy Safety Bimekizumab bDMARD-naïve TNFi-‍inadequate responders
Linkit:	https://doi.org/10.1007/s40744-024-00708-8
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!